Journal
EXPERT REVIEW OF VACCINES
Volume 15, Issue 3, Pages 313-329Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2016.1124762
Keywords
immunogenicity; molecular adjuvant; vaccine delivery; plasmid; DNA vaccine
Categories
Funding
- National Institute of Allergy and Infectious Diseases, National Institutes of Health [HHSN272201400053C, HHSN272200800039C]
Ask authors/readers for more resources
In the two decades since their initial discovery, DNA vaccines technologies have come a long way. Unfortunately, when applied to human subjects inadequate immunogenicity is still the biggest challenge for practical DNA vaccine use. Many different strategies have been tested in preclinical models to address this problem, including novel plasmid vectors and codon optimization to enhance antigen expression, new gene transfection systems or electroporation to increase delivery efficiency, protein or live virus vector boosting regimens to maximise immune stimulation, and formulation of DNA vaccines with traditional or molecular adjuvants. Better understanding of the mechanisms of action of DNA vaccines has also enabled better use of the intrinsic host response to DNA to improve vaccine immunogenicity. This review summarizes recent advances in DNA vaccine technologies and related intracellular events and how these might impact on future directions of DNA vaccine development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available